Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS)

NCT05181592 is registered in ClinicalTrials.gov with GWT-TUD GmbH as lead sponsor.

NCT NCT05181592
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05181592 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIIb, Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Luspatercept in Patients With Lower-risk MDS and Ring-sideroblastic Phenotype (MDS-RS)
Lead sponsor
GWT-TUD GmbH
Phase
Phase 3
Overall status
Active, not recruiting
Start date
October 27, 2021
Completion date
February 28, 2027
Enrollment
70 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

myelodysplastic syndromes